dc.contributor.author | Karabulut, Senem | |
dc.contributor.author | Tas, Faruk | |
dc.contributor.author | Sen, Fatma | |
dc.contributor.author | Ciftci, Rumeysa | |
dc.contributor.author | Duranyildiz, Derya | |
dc.contributor.author | Disci, Rian | |
dc.contributor.author | Sakar, Burak | |
dc.date.accessioned | 2021-03-05T09:42:23Z | |
dc.date.available | 2021-03-05T09:42:23Z | |
dc.date.issued | 2014 | |
dc.identifier.citation | Tas F., Karabulut S., Ciftci R., Sen F., Sakar B., Disci R., Duranyildiz D., "Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy", CANCER CHEMOTHERAPY AND PHARMACOLOGY, cilt.73, ss.1163-1171, 2014 | |
dc.identifier.issn | 0344-5704 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_9f2394fc-b2cc-4c1f-a0a3-df4f4945f787 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/106849 | |
dc.identifier.uri | https://doi.org/10.1007/s00280-014-2450-8 | |
dc.description.abstract | Serum LDH, CEA, and CA19-9 levels are important tumor markers in pancreatic cancer. The purpose of this study was to evaluate the clinical significance of serum LDH, CEA, and CA19-9 levels in metastatic pancreatic cancer (MPC) receiving gemcitabine-based chemotherapy. | |
dc.language.iso | eng | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Onkoloji | |
dc.subject | Eczacılık | |
dc.subject | Temel Eczacılık Bilimleri | |
dc.subject | Yaşam Bilimleri | |
dc.subject | Temel Bilimler | |
dc.subject | Yaşam Bilimleri (LIFE) | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Farmakoloji ve Toksikoloji | |
dc.subject | FARMAKOLOJİ VE ECZACILIK | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | ONKOLOJİ | |
dc.title | Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy | |
dc.type | Makale | |
dc.relation.journal | CANCER CHEMOTHERAPY AND PHARMACOLOGY | |
dc.contributor.department | İstanbul Üniversitesi , , | |
dc.identifier.volume | 73 | |
dc.identifier.issue | 6 | |
dc.identifier.startpage | 1163 | |
dc.identifier.endpage | 1171 | |
dc.contributor.firstauthorID | 33426 | |